Innovation that matters
About JMBIOTECH
JMBIOTECH Corporation Limited (JMB) is a specialist corporation based in South Korea, dedicated to the research and development (R&D), manufacturing and export of innovative premium healthcare
brands for physicians and patients worldwide.
JMB was founded with the goal of establishing a biotech corporation exclusively focused on the following healthcare-related fields:
JMB was incorporated as an independent subsidiary of Jeilmedix Pharmaceutical Corporation in 2009. JMB has merged, acquired and streamlined the core product development and international trade capacities of Jeilmedix Pharmaceutical Co. in order to satisfy the increasing international demand for specialist biotech R&D, customized manufacturing processes and expanding overseas distribution channels. On the other hand, Jeilmedix Pharmaceutical Co. maintains its leading edge marketing and distribution channels across the Korean peninsula for a variety of premium healthcare products provided by global partners, in addition to JMB’s series of signature healthcare products.
JMB puts into practice our ideals of placing our patients and consumers’ needs as our top priority. We define our success through our responsiveness to our clients’ specific needs and aspirations.
History
Small & Medium Business Administration
“TurtlePin Project selected as SMBA government (Small to Medium Business Administration funding project”_2014. DEC. 13)
- 2015. November
Korea Research Institute of Bioscience and Biotechnology
“R&D MOU For TurtlePin” between JMBIOTECH and Korea Research Institute of Bioscience and Biotechnology.
- 2015. July
BioNano Health Guard Research Center
“Micro-needle technology commercialization project” between JMBIOTECH and BioNano Health Guard Research Center (Ministry of Science, ICT, and Future Planning of Korean government)
- 2015. July
IKIN J&M Korea
Diversification of product line. Merger and acquisition over IKIN Corporation limited Korean cosmetic & aesthetic distribution & J&M Korea (Global development of cosmeceutical)
- 2015. April
ISO 13485
ISO 13485 quality management system and CE qualitied.
- 2014. September
TURTLEPIN
TurtlePin PCT patent. (U.S, China, Japan, Canada, and EU)
- 2014. July
MEDIXKOREA
Acquired MedixKorea (Nutraceutical company- Glucomin Glucosamin, Medi-M Multi-Vitamin, Acerola Plus etc.)
- 2014. March
TURTLEPIN(KGMP)
KGMP quality management certified by the Korean Food and Drug administration. Launch of TurtlePin (direct dermal stimulating device)
- 2013. March
JEILMEDIX PHARMACEUTICAL CO.
JMBiotech Corporation Limited was incorporated as an independent venture capital unit from Jeilmedix Pharmaceutical Corporation.
- 2013. March
KOR | ENG | JEILMEDIX
JEILMEDIX PHARMACEUTICAL COMPANY | MARIPOSA® | RIBESKIN® | arcaya® ASIA PACIFIC
Copyright ⓒ 2021 JMBIOTECH CORPORATION LIMITED. ALL RIGHTS RESERVED
